STUDY OF CD163 AND B2M AS MARKERS FOR HODGKIN LYMPHOMA IN HUMAN AND ITS RELATION WITH CLINICO–PATHOLOGICAL BEHAVIOR
Hossam Darwish*, Lamiaa Barakat and Rania Bondok
Background: Hodgkin lymphoma is the most non malignancies at young adult ages, and is a curable disease in most patients. In the present study, our suggestion is to use CD163 and B2M as supplementary markers for the prognosis concerning Hodgkin lymphoma. So, identification of sensitive biomarkers to improve the prognosis related Hodgkin lymphoma is needed. Aim of the work: The aim of present study was to discuss the prognosis utility of serum CD163 and serum B2M in patients for Hodgkin lymphoma during and post therapy the clinical advantage of these markers will be decreased or normal during or post therapy. CD163 will be compared with B2M which is a routinely marker used for diagnosis and in follow up the patients for Hodgkin lymphoma. Results: Serum CD163 was significantly in most patients for Hodgkin lymphoma. The receiver operating characteristic curve (ROC) showed the best cut off values for CD163 and B2M were 5.0 ng/ml and 2.50 mg/l respectively. Area under the curve of CD163 and B2M were significantly 0.79 and 0.78. The sensitivity of CD163 and B2M were 76.7% and 66.7% respectively. Conclusion: Results revealed that serum CD163 may be used as potential prognostic markers for Hodgkin lymphoma patients.
Keywords: Hodgkin lymphoma patients, Cluster of Differentiation 163 (CD163), Beta 2 microglobulin (B2M).
[Full Text Article]